The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4.+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.(No accompanying figure)
